Orshe

According to new research on aging by Pfizer, 51% think they look younger than their age, as the drug company launches its Get Old social forum. Pfizer Chief Medical Officer Dr. Freda Lewis-Hall breaks down the findings on Lunch Break. Photo: Pfizer.

More: Do You Look Younger Than You Are?/a>

Many couples say that space, or “giving each other plenty of space,” is the single most important reason they think their marriage has survived. Elizabeth Bernstein reports on Lunch Break. Photo: Amanda Koster for The Wall Street Journal.

Read more here:  Do You Need More Space in Your Marriage?/a>

Patients with soft-tissue sarcoma, a rare cancer that starts in the body’s muscle or connective tissues, now have a new treatment option.

The FDA late yesterday approved GlaxoSmithKline’s drug Votrient for use in patients with soft-tissue sarcoma, Dow Jones Newswires reports. This is the first new treatment in decades for the cancer. The National Cancer Institute estimates 11,000 cases of soft tissue sarcoma are diagnosed each year in the U.S.

What happens when you’re faced with a life-threatening illness but you can’t get into a clinical trial or wait for lengthy drug development to run its course?

Some patients take matters into their own hands.

As WSJ reports today, a few people with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease, are using a home-brewed drug they hope has similar effects to a compound being tested by Neuraltus Pharmaceuticals in a formal clinical trial.

People 60 and older who want to ward off the risk of getting shingles now stand a better chance of getting the only approved vaccine, Merck’s Zostavax.

By Anjali Athavaley and Peter Loftus

One of the biggest heart-medicine events of the year kicks off Saturday in Chicago. Updates on new devices, drugs and techniques will be discussed during hundreds of sessions at the American College of Cardiology’s annual conference, which runs through Tuesday. Here’s a look at some highlights to watch out for:

With research suggesting that a skin-cancer drug may help Alzheimer’s disease, researchers, physicians and advocacy groups are getting a flurry of calls from patients seeking the drug off-label. Shirley Wang has details on The News Hub. Photo: Science

The rest is here:  Alzheimer Patients Clamor for Skin-Cancer Drug/a>

President Obama on Friday announced a new policy that no longer requires a broad swath of religious organizations to provide employees with contraception coverage in health-insurance plans. Laura Meckler discusses on The News Hub. Photo: AP

Original post:  Obama Proposes New Contraceptive Plan/a>

Certain cystic-fibrosis patients will now have an FDA-approved treatment that targets an underlying cause of their disease.

But that drug — Kalydeco, from Vertex Pharmaceuticals — won’t come cheap.

As Dow Jones Newswires reports, the annual cost will be $294,000. Vertex has set up a patient-assistance program to help patients pay for the treatment.

Bydureon, the once-weekly injection for treating patients with type 2 diabetes, has finally won the FDA’s okay.

As Dow Jones Newswires reports, it’s been a long, bumpy road to approval for the drug’s developer, Amylin Pharmaceuticals.

(Alkermes is behind the extended-release technology used to deliver the drug, a longer-acting version of Amylin’s twice-daily Byetta.)